SEC Company Response from SUNESIS PHARMACEUTICALS INC (VIRX) (CIK 0001061027) (VIRX) — Sep 20, 2005
SUNESIS PHARMACEUTICALS INC (VIRX) (CIK 0001061027)
Date: Sept. 20, 2005 · CIK: 0001061027 · Accession: 0001104659-05-044947
AI Filing Summary & Sentiment
File numbers found in text: 333-121646
Letter
Sunesis Pharmaceuticals, Inc.
341 Oyster Point Boulevard
South San Francisco, California 94080
September 20, 2005
VIA FACSIMILE AND EDGAR TRANSMISSION
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention:
Jeffrey P. Riedler, Assistant Director
Zafar Hasan, Attorney-Advisor
Suzanne Hayes, Attorney-Advisor
Ibolya Ignat, Staff Accountant
James Atkinson, Staff Accountant
Re:
Sunesis Pharmaceuticals, Inc.
Registration Statement on Form S-1
File No. 333-121646
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (No. 333-121646) (the “Registration Statement”) of Sunesis Pharmaceuticals, Inc. (the “Registrant”). We respectfully request that the Registration Statement become effective as of 9:00 a.m., Washington, D.C. time, on September 22, 2005, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling William Davisson at (650) 463-2660. We also respectfully request that a copy of the written order from the Securities and Exchange Commission (the “Commission”) verifying the effective time and date of the Registration Statement be sent to our counsel, Latham & Watkins LLP, Attention: William Davisson, by facsimile to (650) 463-2600.
Please do not hesitate to call William Davisson at (650) 463-2660 if you have any questions regarding this request.
Very truly yours,
/s/ Daryl B. Winter, Ph.D.
Show Raw Text
CORRESP 1 filename1.htm Sunesis Pharmaceuticals, Inc. 341 Oyster Point Boulevard South San Francisco, California 94080 September 20, 2005 VIA FACSIMILE AND EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey P. Riedler, Assistant Director Zafar Hasan, Attorney-Advisor Suzanne Hayes, Attorney-Advisor Ibolya Ignat, Staff Accountant James Atkinson, Staff Accountant Re: Sunesis Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-121646 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (No. 333-121646) (the “Registration Statement”) of Sunesis Pharmaceuticals, Inc. (the “Registrant”). We respectfully request that the Registration Statement become effective as of 9:00 a.m., Washington, D.C. time, on September 22, 2005, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling William Davisson at (650) 463-2660. We also respectfully request that a copy of the written order from the Securities and Exchange Commission (the “Commission”) verifying the effective time and date of the Registration Statement be sent to our counsel, Latham & Watkins LLP, Attention: William Davisson, by facsimile to (650) 463-2600. Please do not hesitate to call William Davisson at (650) 463-2660 if you have any questions regarding this request. Very truly yours, /s/ Daryl B. Winter, Ph.D. Daryl B. Winter, Ph.D. Senior Vice President, General Counsel and Corporate Secretary